63304-81-4

Usage

Uses

Used in Pharmaceutical Industry:
(3-amino-4-methoxyphenyl)acetic acid is used as a building block for the synthesis of various drugs and bioactive compounds. Its versatile structure allows for the production of important pharmaceuticals.
Used in Chemical Industry:
(3-amino-4-methoxyphenyl)acetic acid is used as a valuable chemical for further chemical manipulation and modification, making it widely used in the chemical industry.

Upstream product

• 857544-00-4 2-(4-methoxy-3-nitrophenyl)acetamide 
• 6378-19-4 4-methoxy-3-nitrobenzyl chloride 
• 56245-07-9 2-(4-methoxy-3-nitrophenyl)acetonitrile 
• 6343-93-7 2-(4-methoxyphenyl)acetamide 
• 104-01-8 4-Methoxyphenylacetic acid 
• 31680-08-7 4-methoxy-3-nitrobenzaldehyde 
• 123-11-5 4-methoxy-benzaldehyde 
• 904-42-7 2-Phenyl-4-(3-nitro-4-methoxy-benzyliden)-4H-(1,3)-oxazol-5-on 
• 63304-80-3 (4-methoxy-3-nitrophenyl)acetic acid 

Downstream Products

• 857544-42-4 [3-(3-carboxy-2-nitro-phenylsulfanyl)-4-methoxy-phenyl]-acetic acid 
• 160857-73-8 (3-azido-4-methoxyphenyl)ketene 
• 179469-45-5 3-azido-4-methoxyphenylacetic acid 
• 104967-36-4 (3-mercapto-4-methoxy-phenyl)-acetic acid 
• 1131-94-8 homoisovanillic acid 

Relevant academic research and scientific papers

RORGAMMA MODULATORS AND USES THEREOF

The present invention provides novel compounds of formula (la) that are modulators of RORgamma. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the modulation of RORgamma has therapeutic effects, for instance in autoimmune diseases, autoimmune-related diseases, inflammatory diseases, metabolic diseases, fibrotic diseases, or cholestatic diseases.

N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT

The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

Diastereoselective Synthesis of Cularine Alkaloids via Enium Ions and an Easy Entry to Isoquinolines by Aza-Wittig Electrocyclic Ring Closure

In preliminary communications, we reported the diastereoselective synthesis of cularine and sarcocapnine via the intramolecular ring closure of nitrenium and oxenium ions, a new highly diastereoselective reductive methylation with (+)-8-phenylmenthyl chloroacetate followed by reduction with sodium borohydride, and a facile entry to the isoquinoline precursors by aza-Wittig electrocyclic ring closure. We now report the full details of the syntheses of (+)-O-demethylcularine, (+)-cularine, (+)-sarcocapnidine, (+)-sarcocapnine, and (+)-crassifoline and describe different methods of synthesis of their precursors.